Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMB29S)

Drug Name

Orotate Drug Info

Synonyms

73-97-2; Orotic acidanion; AC1LSPNG; CHEBI:30839; CTK5D9013; DTXSID80363448; PXQPEWDEAKTCGB-UHFFFAOYSA-M; AG-G-93379; 2,4-dioxo-1H-pyrimidine-6-carboxylate; CJ-15820; 21317-EP2314295A1; 21317-EP2284172A1; 21317-EP2281559A1; 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylate; 4-Pyrimidinecarboxylicacid, 1,2,3,6-tetrahydro-2,6-dioxo-, ion(1-)

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 1492348
ChEBI ID: CHEBI:30839
CAS Number: CAS 73-97-2
TTD Drug ID: DMMB29S
VARIDT Drug ID: DR00157

Molecule-Related Drug Atlas

Molecule Type:

DTT

DTP

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Transported By Urate anion exchanger 1 (SLC22A12)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oxypurinol	DMURH4X	Heart failure	BD10-BD13	Phase 2/3	[3]
Uric acid	DMA1MKT	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------

Drug(s) Targeting Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[5]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[6]
Teriflunomide	DMQ2FKJ	Hyperlipidaemia	5C80	Approved	[7]
Atovaquone	DMY4UMW	Fungal infection	1F29-1F2F	Approved	[8]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[9]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[10]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[10]
Lauryl Dimethylamine-N-Oxide	DM3W2OE	Discovery agent	N.A.	Investigative	[10]
1,4-Naphthoquinone	DMTCMH7	Discovery agent	N.A.	Investigative	[9]
Dihydroorotate	DM76BGZ	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Plasmodium Dihydroorotase (Malaria dho)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lysine Nz-Carboxylic Acid	DMW1YK3	Discovery agent	N.A.	Investigative	[10]
Dihydroorotate	DM76BGZ	Discovery agent	N.A.	Investigative	[10]
5-Fluoro orotate	DMLSC10	Discovery agent	N.A.	Investigative	[1]
5-bromo orotate	DM0HCG6	Discovery agent	N.A.	Investigative	[1]
N-Carbamoyl-L-Aspartate	DMJ13TR	Discovery agent	N.A.	Investigative	[10]
5-iodo orotate	DMDKFIO	Discovery agent	N.A.	Investigative	[1]
5-methyl orotate	DMYNFIP	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Plasmodium Dihydroorotase (Malaria dho)	TT09NOX	A9CSR1_PLAFA	Inhibitor	[1]
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)	TT3PQ2Y	PYRD_PLAF7	Inhibitor	[1]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Urate anion exchanger 1 (SLC22A12)	DT2WLAD	S22AC_HUMAN	Substrate	[2]

------------------------------------------------------------------------------------

References

1	Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
2	Human urate transporter 1 (hURAT1) mediates the transport of orotate. J Physiol Sci. 2011 May;61(3):253-7.
3	Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos. 2005 Dec;33(12):1791-5.
4	Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter. J Pharmacol Exp Ther. 2007 Jan;320(1):211-7.
5	The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
6	Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
7	Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8.
8	Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
9	Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
10	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
11	Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors. Biochem Pharmacol. 1988 Oct 15;37(20):3807-16.